Author Archives: admin


Stem Cell Clinic > Articles by: admin

Gene and Cell Therapy Defined – asgct.org

By Uncategorized

Gene therapy is a field of biomedical research with the goal of influencing the course of various genetic and acquired (so-called multi factorial) diseases at the DNA/RNA level. Cell therapy aims at targeting various diseases at the cellular level, i.e. by restoring a certain cell population or using cells as carriers of therapeutic cargo. For many diseases, gene and cell therapy are applied in combination. In addition, these two fields have helped provide reagents, concepts, and techniques that are illuminating the finer points of gene regulation, stem cell lineage, cell-cell interactions, feedback loops, amplification loops, regenerative capacity, and remodeling.

Gene therapy is the introduction, removal, or change in the content of a persons genetic code with the goal of treating or curing a disease. Moreover, it is a set of strategies that modify the expression of an individuals genes or repair abnormal genes. Each strategy involves the administration of a specific nucleic acid (DNA or RNA). Nucleic acids are normally not taken up by cells, thus special carriers, so-called 'vectors' are required. Vectors can be of either viral or non-viral nature.

Cell therapy is defined as the administration of living whole cells for the patient for the treatment of a disease. The origin of the cells can be from the same individual (autologous source) or from another individual (allogeneic source). Cells can be derived from stem cells, such as bone marrow or induced pluripotent stem cells (iPSCs), reprogrammed from skin fibroblasts or adipocytes. Stem cells are applied in the context of bone marrow transplantation directly. Other strategies involve the application of more or less mature cells, differentiated in vitro (in a dish) from stem cells.

Historically, the discovery of recombinant DNA technology in the 1970s provided the tools to efficiently develop gene therapy. Scientists used these techniques to readily manipulate bacterial and viral genomes, isolate genes, identify mutations involved in human diseases, characterize and regulate gene expression and produce human proteins from genes (e.g. production of insulin in bacteria revolutionized medicine). Later, various viral and non-viral vectors were developed along with the development of regulatory elements (e.g. promoters that regulate gene expression), which are necessary to induce and control gene expression. Gene transfer in animal models of disease have been attempted and led to early success. Various routes of administrations have been explored (injection into the bloodstream, into the ventricles of the brain, into muscle etc).

The development of suitable gene therapy treatments for many genetic diseases and some acquired diseases has encountered many challenges, such as immune response against the vector or the inserted gene. Current vectors are considered very safe and recent gene therapy trials documented excellent safety profile of modern gene therapy products. Further development involves uncovering basic scientific knowledge of the affected tissues, cells, and genes, as well as redesigning vectors, formulations, and regulatory cassettes for the genes. While effective long-term treatments for many genetic and inherited diseases are elusive today, some success is being observed in the treatment of several types of immunodeficiency diseases, cancers, and eye disorders.

Historically, blood transfusions were the first type of cell therapy and are now considered routine. Bone marrow transplantation has also become a well-established medical treatment for many diseases, including cancer, immune deficiency and others. Cell therapy is expanding its repertoire of cell types for administration. Cell therapy treatment strategies include: isolation and transfer of specific stem cell populations, induction of mature cells to become pluripotent cells, administration of effector cells and reprogramming of mature cells into iPSCs. Administration of large numbers of effector cells has benefited cancer patients, transplant patients with unresolved infections, and patients with vision problems.

Several diseases benefit most from treatments that combine the technologies of gene and cell therapy. For example, some patients have a severe combined immunodeficiency disease (SCID) but unfortunately, do not have a suitable donor of bone marrow. Scientists have identified that patients with SCID are deficient in adenosine deaminase gene (ADA-SCID), or the common gamma chain located on the X chromosome (X-linked SCID). Several dozen patients have been treated with a combined gene and cell therapy approach. Each individuals hematopoietic stem cells were treated with a viral vector that expressed a copy of the relevant normal gene. After selection and expansion, these corrected stem cells were returned to the patients. Many patients improved and required less exogenous enzymes. However, some serious adverse events did occur and their incidence is prompting development of theoretically safer vectors and protocols. The combined approach also is pursued in several cancer therapies.

Genome editing (gene editing) has recently gained significant attention, due to the discovery and application of the clustered regularly interspaced short palindromic repeats (CRISPR) system. Actually, genome editing dates back several years and earlier generation genome editing systems are currently tested in clinical trials (such as zinc-finger nucleases). The aim of genome editing is to disrupt a disease-causing mutation or correct faulty genes at the chromosomal DNA. Genome editing can be performed in the patients own cells in vitro and edited cells can be administered to the patient (thus genome editing can be combined with cell therapy). However, it is also possible to perform genome editing in vivo by administering the genome editing agent packaged in viral and non-viral vectors.

See the rest here:
Gene and Cell Therapy Defined - asgct.org

Stem Cells – The Hastings Center

By Stem Cell Medical Center

By Insoo Hyun

Stem cells are undifferentiated cells that have the capacity to renew themselves and to specialize into various cell types, such as blood, muscle, and nerve cells. Embryonic stem cells, derived from five-day-old embryos, eventually give rise to all the different cells and organ systems of the embryo. Embryonic stem cells are pluripotent, because they are capable of differentiating along each of the three germ layers of cells in the embryo, as well as producing the germ line (sperm and eggs). The three germ layers are the ectoderm (skin, nerves, brain), the mesoderm (bone, muscle), and the endoderm (lungs, digestive system).

During later stages of human development, minute quantities of more mature stem cells can be found in most tissue and organ systems, such as bone marrow, the skin, and the gut. These are somatic stem cells, responsible for renewing and repairing the bodys specialized cells. Although the lay public often refers to them as adult stem cells, researchers prefer to call them multipotent because they are less versatile than pluripotent stem cells, and because they are present from the fetal stage of development and beyond. Multipotent stem cells can only differentiate into cells related to the tissue or organ systems from which they originated for instance, multipotent blood stem cells in bonemarrow can develop into different types of blood cells, but not into nerve cells or heart cells.

While multipotent stem cell research has been around for nearly 50 years and has led to clinical therapies for leukemia and other blood disorders, the field of human embryonic stem cell research is still relatively new, and basic discoveries have yet to be directly transitioned into clinical treatments. Human embryonic stem cells were first isolated and maintained in culture in 1998 by James Thomson and colleagues at the University of Wisconsin. Since then, more than a thousand different isolateslines of self-renewing embryonic stem cellshave been created and shared by researchers worldwide.

The main ethical and policy issues with stem cells concern the derivation and use of embryonic stem cells for research. A vocal minority of Americans objects to the destruction of embryos that occurs when stem cells are derived. Embryonic stem cell research is especially controversial for those who believe that five-day-old preimplantation human embryos should not be destroyed no matter how valuable the research may be for society.

To bypass this ethical controversy, the Presidents Council on Bioethics recommended in 2005 that alternative sources of pluripotent stem cells be pursued. Some alternatives have been developed, most notably, the induced pluripotent stem (iPS) cells human skin cells and other body cells reprogrammed to behave like embryonic cells. But embryonic stem cell research will remain needed because there are some questions only they have the potential to answer.

Embryonic stem cells are necessary for several aims of scientific and biomedical research. They include addressing fundamental questions in developmental biology, such as how primitive cells differentiate into more specialized cells and how different organ systems first come into being. By increasing our knowledge of human development, embryonic stem cells may also help us better understand the causes of fetal deformations.

Other important applications lie in the areas of disease research and targeted drug development. By deriving and studying embryonic or other pluripotent stem cells that are genetically-matched to diseases such as Parkinsons disease and juvenile diabetes, researchers are able to map out the developmental course of complex medical conditions to understand how, when, and why diseased specialized cells fail to function properly in patients. Such disease-in-a-dish model systems provide researchers with a powerful new way to study genetic diseases. Furthermore, researchers can aggressively test the safety and efficacy of new, targeted drug interventions on tissue cultures of living human cells derived from disease-specific embryonic stem cells. This method of testing can reduce the risks associated with human subjects research.

One possible way of deriving disease-specific stem cells is through a technique called somatic cell nuclear transfer (SCNT), otherwise known as research cloning. By replacing the DNA of an unfertilized egg with the DNA of a cell from a patients body, researchers are able to produce embryonic stem cells that are genetically-matched to the patient and his or her particular disease. SCNT, however, is technically challenging and requires the collection of high-quality human eggs from female research volunteers, who must be asked to undergo physically burdensome procedures to extract eggs.

A much more widespread and simpler technique for creating disease-specific stem cells was pioneered in 2006 by Shinya Yamanaka and colleagues in Kyoto, Japan. They took mouse skin cells and used retroviruses to insert four genes into them to to create iPS cells. In 2007, teams led by Yamanaka, James Thomson, and George Daley each used similar techniques to create human iPS cells. The iPS cell approach is promising because disease-specific stem cells could be created using skin or blood samples from patients and because, unlike SCNT, it does not require the procurement of human eggs for research.

However, despite these advances, scientists do not believe iPS cells can replace human embryonic stem cells in research. For one, embryonic stem cells must be used as controls to assess the behavior and full scientific potential of iPS cells. Furthermore, iPS cells may not be able to answer some important questions about early human development. And safety is a major issue for iPS cell research aimed at clinical applications, since the cell reprogramming process can cause harmful mutations in the stem cells, increasing the risk of cancer. In light of these and other concerns, iPS cells may perhaps prove to be most useful in their potential to expand our overall understanding of stem cell biology, the net effect of which will provide the best hope of discovering new therapies for patients.

Many who oppose embryonic stem cell research believe for religious or other personal reasons that all preimplantation embryos have a moral standing equal to living persons. On the other hand, those who support embryonic stem cell research point out that not all religious traditions grant full moral standing to early-stage human embryos.

According to Jewish, Islamic, Hindu, and Buddhist traditions, as well as many Western Christian views, moral standing arrives much later during the gestation process, with some views maintaining that the fetus must first reach a stage of viability where it would be capable of living outside the womb. Living in a pluralistic society such as ours, supporters argue, means having to tolerate differences in religious and personal convictions over such theoretical matters as when, during development, moral standing first appears.

Other critics of embryonic stem cell research believe that all preimplantation embryos have the potential to become full-fledged human beings and that they should never have this potential destroyed. In response, stem cell supporters argue that it is simply false that all early-stage embryos have the potential for complete human life many fertility clinic embryos are of poor quality and therefore not capable of producing a pregnancy (although they may yield stem cells). Similarly, as many as 75% to 80% of all embryos created through intercourse fail to implant. Furthermore, no embryos have the potential for full human life until they are implanted in a womans uterus, and until this essential step is taken an embryos potential exists only in the most abstract and hypothetical sense.

Despite the controversies, embryonic stem cell research continues to proceed rapidly around the world, with strong public funding in many countries. In the U.S., federal money for embryonic stem cell research is available only for stem cell lines that are on the National Institutes of Health stem cell registry. However, no federal funds may be used to derive human embryonic stem cell lines; NIH funds may only be used to study embryonic stem cells that were derived using other funding sources.

Despite the lack of full federal commitment to funding embryonic stem cell research in the U.S., there are wide-ranging national regulatory standards. The National Academy of Sciences established guidelines in 2005 for the conduct of human embryonic stem cell research. (See Resources.) According to these guidelines, all privately and publicly funded scientists working with embryonic stem cells should have their research proposals approved by local embryonic stem cell research oversight (ESCRO) committees. ESCRO committees are to include basic scientists, physicians, ethicists, legal experts, and community members to look at stem-cell-specific issues relating to the proposed research. These committees are also to work with local ethics review boards to ensure that the donors of embryos and other human materials are treated fairly and have given their voluntary informed consent to stem cell research teams. Although these guidelines are voluntarily, universities and other research centers have widely accepted them.

At the global level, in 2016 the International Society for Stem Cell Research (ISSCR) released a comprehensive set of professional guidelines for human stem cell research, spanning both bench and clinical stem cell research. (See Resources.) Unlike the NAS guidelines, the ISSCR guidelines go beyond American standards, adding, for example, the recommendation that stem cell lines be banked and freely distributed to researchers around the world to facilitate the fields progress on just and reasonable terms.The potential for over-commercialization and restrictive patenting practices is a major problem facing the stem cell field today, which may delay or reduce the broad public benefit of stem cell research. The promise of broad public benefit is one of thejustifying conditions for conducting stem cell research; without the real and substantial possibility for public benefit, stem cell research loses one of its most important moral foundations.

However, providing useful stem-cell-based therapies in the future is not a simple proposition, either. Developing a roadmap to bring stem cell research into the clinic will involve many complex steps, which the new ISSCR guidelines help address. They include:

These and other difficult issues must be sorted out if stem cell research in all its forms is to fulfill its promise.

STEM CELL GLOSSARY

Newer ethical issues in stem cell research go far beyond the embryo debate, since they encompass all stem cell types, not just human embryonic stem cells, and because they involve human subjects who, despite what one may think about the moral status of preimplantation embryos, are unequivocally moral persons. No other emerging issue better encapsulates the above concern than the growing phenomenon of stem cell tourism. At present, stem cell-based therapies are the clinical standard of care for only afew conditions, such as hematopoietic stem cell transplants for leukemia and epithelial stem cell-based treatments for burns and corneal disorders. Unfortunately, some unscrupulous clinicians around the world are exploiting patients hopes by purporting to provide for large sums of money effective stem cell therapies for many other conditions. These so-called stem cell clinics advance claims about their proffered stem cell therapies without credible scientific rationale, transparency, oversight, or patient protections.

The administration of unproven stem cell interventions outside of carefully regulated research protocols endangers patients and jeopardizes the legitimate progress of translational stem cell scientific research. Patients who travel for unproven stem cell therapies put themselves at risk of physical and financial harm.

The ISSCR guidelines are a good point for thinking about this important problem. The guidelines allow for exceptional circumstances in which clinicians might attempt medically innovative care in a very small number of seriously ill patients, subject to stringent oversight criteria. These criteria include: independent peer review of the proposed innovative procedure and its scientific rationale; institutional accountability; rigorous informed consent and close patient monitoring; transparency; timely adverse event reporting; and a commitment by clinician-scientists to move to a formal clinical trial in a timely manner after experience with at most a few patients. By juxtaposing some current stem cell clinics against the standards outlined in the ISSCR guidelines, one may easily identify some clinics shortcomings and call into question the legitimacy of their purported claims of providing innovative care to patients.

Moving beyond past debates about embryo status to issues concerning the uses of all varieties of stem cells, one can begin to focus the bioethical discourse on areas that have a much broader consensus base of shared values, such as patient and research subject protections and justice. Justice may also call on regulatory and oversight bodies to include a greater involvement of community and patient advocates in the oversight of research. Dealing with the bioethics of stem cell research demands that we wrestle with these and other tough questions.

Insoo Hyun, PhD, is an associate professor of bioethics at Case Western Reserve University.

Read more:
Stem Cells - The Hastings Center

Stem Cell | Regenerative medicine | 2019 | Conference …

By Stem Cell Medicine

Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contactstemcell@alliedevents.org

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

If, due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to contacts@alliedacademies.com Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified. Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.

Refund Policy.

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy

Orders are available:

Accommodation Cancellation Policy

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

Visit link:
Stem Cell | Regenerative medicine | 2019 | Conference ...

About Stem Cell Therapy – Kansas Regenerative Medicine

By Uncategorized

In regenerative medicine today, adult stem cells hold the most promise for cell-based therapies. There are two main types of stem cells, adult and embryonic, which require unique means of collection and deployment.

Early research in the field was often associated with the controversial use of embryonic stem cells. Today, the cutting-edge of the science focuses on Mesenchymal stem cells found in an adults blood, bone marrow and fatty deposits. At KRMC we never use embryonic stem cells.

Adipose Stem Cells

Cell therapy around the world is shifting its focus from bone marrow based cells to adipose (fat) derived cells. These cells are easy to obtain and are generally robust. Adipose fat is an abundant and reliable source of stem cells. The best quality adipose cells are derived from the enzymatic digestion of liposuctioned fat which can be performed in a nearly painless, outpatient procedure.

The quality of stem cells deployed appear to be related directly to the clinical success and favorable outcomes of a procedure. Once adipose derived stem cells are deployed into an affected area of a patient body, the cells have the potential to:

Bone Marrow Derived Stem Cells

While Mesenchymal stem cells derived from bone marrow offer the same benefits as Adipose derived stem cells, there are two reasons KRMC does not currently collect stem cells from bone marrow.

A Comparison: Bone Marrow and Adipose

Adult Stem cells are obtained by different methods, each offering a different experience. The two most common methods are the older, bone marrow derived method and the increasingly popular Fat (Adipose) derived method.

Whether adult mesenchymal stem cells come from bone marrow or from fat does not appear to make a difference in clinical results. Some centers claim that bone marrow derived cells are superior to fat derived cells but there is no clinical evidence to substantiate this claim. While there are more studies on bone marrow cells, there is no evidence as to their clinical superiority.

It is important to understand that the word bone in bone marrow is sometimes used to implying that an orthopedic source might be better for treating orthopedic conditions such as cartilage regeneration. In fact, bone marrow is part of the reticulo-endothelial system and happens to be found in the center of bone. All of these types of cells are equally undifferentiated and have the potential to differentiate into mature functional tissues.

For many disease types such as cardiac pathology, adipose derived cells appear to be showing superiority to bone marrow derived cells. This may be related to the well documented qualitative and quantitative attrition in bone marrow stem cell counts related to age and chronic illness (chronic disease causes bone marrow suppression). Such changes in the number of cells over time and the quality of cells dependent on health have not been seen in fat derived stem cells. Fat derived cells are a natural choice for our investigatory work considering their easy and rapid availability in extremely high numbers.

Embryonic Stem Cells

At KRMC, we never use embryonic stem cells. Embryonic (ES) Stem cells are isolated from the inner cell mass of blastocysts of preimplantation-stage embryos. These cells require specific signals to differentiate to the desired cell type. If simply injected directly, they will differentiate into many different types of cells, resulting in a tumor derived from this abnormal pluripotent cell development (a teratoma). The directed differentiation of ES cells and avoidance of transplant rejection are just two of the hurdles that ES cell researchers still face. In addition, Embryonic stem cells are associated with ethical considerations and limitations.

Amniotic stem cells

KRMC does not use amniotic stem cells. Commercially available sources of stem cells, such as amniotic products, are not collected from ones own body. These cells are gamma radiated by manufacturers and are, therefore, not live cells.

Read the original:
About Stem Cell Therapy - Kansas Regenerative Medicine

Cigarette lighter using rechargeable AA batteries …

By Stell Cell Research

NiCads have a lower internal resistance than NiMH. SLA even lower.

Having said that, I'd approach this as an academic exercise rather than as a practical project opportunity

This page http://www.buchmann.ca/article4-page1.asp (and I think they mean milliohms rather than milliwatts in the table) gives you some indication of internal resistances for cell types. (remember to divide these figures by the number of cells to get the per-cell internal resistance)

I think you'd have a better chance with D cells (certainly SLA cells are available in that size)

A major issue would be the connection to the cells. You would have to use cells that are terminated with solder tags rather than bare cells -- the connection resistance would be far too high.

You would need to look at the datasheets on individual cells to determine if the discharge rates are possible for the cell.

Another issue would be that you would almost certainly need to generate another higher voltage source to power your regulator. It is difficult to imagine any of the more efficient designs starting up on their own from 1.5V. You might need a more specialised "joule thief" type of inverter to generate an initial 12V rail to power the main inverter before using the generated 12V rail for continuous operation (or not -- you could use 2 regulators, it's not like a bit of inefficiency here would be a real issue).

More practically, you may be better off creating your own specialised "cigarette lighter" from a coil of nichrome wire of sufficient length to glow red hot from just a 1.2V supply. Since this device would be small enough to turn on when brought to the cigarette, it need not require the relatively large thermal mass of a conventional car cigarette lighter.

I would estimate that you could probably create a device that used perhaps only 10W (i.e. 8A) and would only need to be operated for a couple of seconds. The major issue here would be the contact resistance and the switch. It may be sensible to use a small inverter to provide gate voltage for a high current mosfet that has a very low RDSon.

At a minimum, I think you'd still be looking at a sub-C sized cell.

OK, here's the specs I found on a sub-C cell. It is rated for up to 30A discharge. http://www.gpbatteries.com/pic/330SCH-ZRS1161rev2.pdf Note the voltage at 30A, also note that the effective capacity is much lower, still it looks like you'd get 6 minutes use at 30A which is pretty good.

This page has more battery types listed: http://www.rechargeable-battery-review.com/data-sheets/battery-specs/gp-battery-data-sheets.html

From a quick look, it appears that the AA sized cells top out at a recommended max of 6.6A. (D cells go to 50A)

See the original post:
Cigarette lighter using rechargeable AA batteries ...

Barnesville.com

By Stell Cell Research

Doris White, 1923 2019

Doris May Chinery White, 95, died January 5, 2019, in Rocky Face, Georgia. Doris was the youngest of two daughters born to Daniel Henry and Dora May Decker Chinery on June 3, 1923, on Staten Island, one of the five boroughs of New York City. Around the age of three years, Doris lost her mother to influenza. Raised by their father, with the help of nearby maternal aunts, Doris and her sister, Constance Henrietta (Connie), enjoyed a happy, comfortable childhood in their home on Rainbow Avenue.

In 1942 Doris graduated from Port Richmond High School, just months after her beloved father died of a stroke. She and her sister were required by circumstances to support themselves, though Doris still managed to take some courses at Seton Hall College. During World War II, Doris worked in the Empire State Building for the Electric Boat Company, which produced PT boats for the Navy. After a time, Doris older sister Connie pursued a career overseas, working for an electric company, Marconi's Wireless Telegraph Company. Connie never married and died in 1973 in New York City.

Following WW II, Doris was introduced to William C. White by her friend and his younger sister, Catherine (Kitty). A graduate of the College of the Holy Cross in Worcester, Massachusetts, and a returning Army officer who had served in England for five years, Bill White was the son of a New York City physician who practiced medicine from an office in his brownstone home in the Irish neighborhood of Hells Kitchen near Times Square. Bill and his sister Kitty were among the youngest of ten siblings; their oldest sister, Bessie, was a nun in the order of the Cenacle Sisters.

On June 14, 1947, Doris and Bill were married in Manhattan, New York City, and they enjoyed over 50 years of marriage, until Bill died on August 28, 1997, in Thomaston, Georgia. In their early married life, they lived in Manhattan and also in Danbury, Connecticut, and in Freeport, New York, on Long Island, as Bill pursued a business career. In 1955, they moved briefly to Jacksonville, Florida, and then on to Atlanta, Georgia, where they lived in the Chamblee and Dunwoody areas.

In 1964, Doris and Bill moved their family to Yatesville, Georgia, seventy miles south of Atlanta, in Upson County (west of Macon). There, Bill began an almost 20-year career with the Federal Paper Board Company in the county seat of Thomaston; he also served a term on the Yatesville City Council. As her children grew older, Doris worked in a clerical capacity at the Marist School in Atlanta, Upson Regional Hospital in Thomaston, and Shallowford Hospital in Atlanta.

Doris was the mother of 7 children: Frances Mary (deceased as a newly born infant), Daniel C. (Sarah Wynn), Mary A., William C. Jr. (Penny), Paul J. (Sue), Theodore M., and John F. (Carolyn). Also known as Gram (while her husband was known as Pop), Doris delighted in her role as grandmother to eleven grandchildren: Leslie Carter, Chas White, Katie White, Kelie White, Kimberly Mann, Kristin White, Erin White, Garrett Mann, Gina White, Jeff Mann, and Henry White. Doris is also survived by nine great-grandchildren.

A memorial service will be held at a later date. In lieu of flowers, memorial contributions may be made to the Bill and Doris White Scholarship at Gordon State College (www.gordonstate.edu/fndscholarships and http://www.gordonstate.edu/alumni/give-to-gordon.html). As the parents of six children who were educated in the Upson County, Georgia, Public School System, Bill and Doris White developed a deep respect for the rural teachers and administrators who made the education of their children such a rich and rewarding experience. Realizing the importance for all students to continue onto higher education and realizing that many rural students are economically challenged and that not all students reach their full academic potential in high school, it is the intention of the Bill and Doris White Scholarship to provide financial assistance and recognition to students who might not otherwise receive it.

Donations may be made on-line or mailed to Gordon State College Foundation at: GSC Foundation, 419 College Drive, Barnesville, GA 30204. Donation checks may be made out to the Gordon State College Foundation. In memory of Doris White may be written on the FOR line of the check or a note may be enclosed with the donation indicating the intended scholarship.

Link:
Barnesville.com

YNS Cosmeceutical Skincare – Top Skin Care Products

By Stell Cell Research

Hi, I would like to express my extreme pleasure in Anne's product's. I have very sensitive skin and Anne's products are the only products that I have been able to use that do not cause irritation and/ or further damage. I could be wrong by a year but I do believe I have been a client for at least ten years. I would highly recommend her services and products to everyone.. I promise you will not be disappointed. I use radiance, infusion, cell tight and the cleansing gel. All 4 of these products either singularly or 2 or 3 or all 4 in the same day at the right time have an amazing ability to be effective for all the necessary needs my skin requires. In addition, I have tried many other products spending thousands of dollars, prior to meeting Anne. I am perfectly happy and have not tried another product since. In addition, after so many years of raw skin, blotchy, uneven, and ruddy red skin, I am pain free with beautiful healthy skin. Finally, I am stopped on a regular basis with compliments about my skin and what do I do. I say YNS that the answer and I share Anne's number. Natasha and Anne thank you so much. God Bless you and your company. Beat Regards, Tammyread more

Originally posted here:
YNS Cosmeceutical Skincare - Top Skin Care Products

Best Bourbon. Rankings of Best Bourbon – Bourbon Reviews

By Stell Cell Research

Evan Williams 23 year Old

More Info Visit website

G

VG

E

Basil Haydens 8 year old Kentucky Straight Bourbon

More Info Visit website

G

VG

E

Parkers Heritage Collection "Golden Anniversary" Bourbon

More Info Visit website

G

VG

E

1792 Ridgemount Reserve

More Info Visit website

G

VG

E

Pappy Van Winkles Family Reserve 23yr

More Info Visit website

G

VG

E

Baker's Kentucky Straight Bourbon Whiskey

More Info Visit website

G

VG

E

Jim Beam Original

More Info Visit website

G

VG

E

Glen Garioch 46 years old 1958

More Info Visit website

G

VG

E

Booker's True Barrel Bourbon

More Info Visit website

G

VG

E

Angel's Envy

More Info Visit website

G

VG

E

Read the original:
Best Bourbon. Rankings of Best Bourbon - Bourbon Reviews

Vitality Healthcare – Home

By Stem Cell Clinic

Last Updated on November 29, 2016. This privacy policy is effective immediately.

At Vitality Healthcare(the Company orWe), we respect your privacy and are committed to protecting it through our compliance with this policy.

This policy describes the types of information we may collect from you or that you may provide when you visit this website (our Website) and our practices for collecting, using, maintaining, protecting and disclosing that information.

This policy applies to information we collect:

It does not apply to information collected by:

Please read this policy carefully to understand our policies and practices regarding your information and how we will treat it. If you do not agree with our policies and practices, your choice is not to use our Website. By accessing or using this Website, you agree to this privacy policy. This policy may change from time to time. Your continued use of this Website after we make changes is deemed to be acceptance of those changes, so please check the policy periodically for updates.

Our Website is not intended for children under 13 years of age. No one under age 13 may provide any personal information to or on the Website. We do not knowingly collect personal information from children under 13. If you are under 13, do not use or provide any information on this Website or on or through any of its features/register on the Website, make any purchases through the Website, use any of the interactive or public comment features of this Website or provide any information about yourself to us, including your name, address, telephone number, e-mail address or any screen name or user name you may use. If we learn we have collected or received personal information from a child under 13 without verification of parental consent, we will delete that information. If you believe we might have any information from or about a child under 13, please contact us via our contact us link.

We collect several types of information from and about users of our Website, including information:

We collect this information:

The information we collect on or through our Website may include:

You also may provide information to be published or displayed (hereinafter, posted) on public areas of the Website, or transmitted to other users of the Website or third parties (collectively, User Contributions). Your User Contributions are posted on and transmitted to others at your own risk. Although we limit access to certain pages/you may set certain privacy settings for such information by logging into your account profile, please be aware that no security measures are perfect or impenetrable. Additionally, we cannot control the actions of other users of the Website with whom you may choose to share your User Contributions. Therefore, we cannot and do not guarantee that your User Contributions will not be viewed by unauthorized persons.

As you navigate through and interact with our Website, we may use automatic data collection technologies to collect certain information about your equipment, browsing actions and patterns, including:

We also may use these technologies to collect information about your online activities over time and across third-party websites or other online services (behavioral tracking). The information we collect automatically is statistical data and does not include personal information, but we may maintain it or associate it with personal information we collect in other ways or receive from third parties. It helps us to improve our Website and to deliver a better and more personalized service, including by enabling us to:

The technologies we use for this automatic data collection may include:

We do not collect personal Information automatically, but we may tie this information to personal information about you that we collect from other sources or you provide to us.

Some content or applications, including advertisements, on the Website are served by third-parties, including advertisers, ad networks and servers, content providers and application providers. These third parties may use cookies alone or in conjunction with web beacons or other tracking technologies to collect information about you when you use our website. The information they collect may be associated with your personal information or they may collect information, including personal information, about your online activities over time and across different websites and other online services. They may use this information to provide you with interest-based (behavioral) advertising or other targeted content.

We do not control these third parties tracking technologies or how they may be used. If you have any questions about an advertisement or other targeted content, you should contact the responsible provider directly.

We use information that we collect about you or that you provide to us, including any personal information:

We may use the information we have collected from you to enable us to display advertisements to our advertisers target audiences. Even though we do not disclose your personal information for these purposes without your consent, if you click on or otherwise interact with an advertisement, the advertiser may assume that you meet its target criteria.

We may disclose aggregated information about our users, and information that does not identify any individual, without restriction.

We may disclose personal information that we collect or you provide as described in this privacy policy:

We may also disclose your personal information:

We strive to provide you with choices regarding the personal information you provide to us. We have created mechanisms to provide you with the following control over your information:

You may send us an e-mail via our contact link to request access to, correct or delete any personal information that you have provided to us. We cannot delete your personal information except by also deleting your user account. We may not accommodate a request to change information if we believe the change would violate any law or legal requirement or cause the information to be incorrect.

If you delete your User Contributions from the Website, copies of your User Contributions may remain viewable in cached and archived pages, or might have been copied or stored by other Website users. Proper access and use of information provided on the Website, including User Contributions, is governed by our terms of use.

California Civil Code Section 1798.83 permits users of our Website that are California residents to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes. To make such a request, please contact us via the Contact Us link.

We have implemented measures designed to secure your personal information from accidental loss and from unauthorized access, use, alteration and disclosure

The safety and security of your information also depends on you. Where we have given you (or where you have chosen) a password for access to certain parts of our Website, you are responsible for keeping this password confidential. We ask you not to share your password with anyone.

Unfortunately, the transmission of information via the internet is not completely secure. Although we do our best to protect your personal information, we cannot guarantee the security of your personal information transmitted to our Website. Any transmission of personal information is at your own risk. We are not responsible for circumvention of any privacy settings or security measures contained on the Website.

It is our policy to post any changes we make to our privacy policy on this page. If we make material changes to how we treat our users personal information, we will notify you by e-mail to the e-mail address specified in your account and/or through a notice on the Website home page. The date the privacy policy was last revised is identified at the top of the page. You are responsible for ensuring we have an up-to-date active and deliverable e-mail address for you, and for periodically visiting our Website and this privacy policy to check for any changes.

To ask questions or comment about this privacy policy and our privacy practices, contact via our Contact Us link.

Thank You for Visiting the Website.

Go here to see the original:
Vitality Healthcare - Home

Original Medicine Wellness Center – Functional Medicine …

By Stem Cell Medicine

Stem Cell Therapy

Today we are seeing incredible results with stem cells in treating heart disease, brain disease, diabetes, cancer, arthritis, spinal cord injuries, burns, macular degeneration, and much more.

Optimize Brain Health

Having brain fog or difficulty focusing can be the result of many factors including hormonal imbalance, gut health, and neurotransmitter imbalance.

Educational Classes

We'll provide you with education and resources to better support your health as an individual as well as for your family.

Hormone Solutions

Our goal is to balance hormones through fixing the underlying problems that exist in the organs and glands. Rather than giving the body a hormone, why not get the body to produce its own?

Original Medicine

We approach health with the idea that the body is a self-healing, self-regulating and self-developing organism.

CONTACT USOriginal Medicine Wellness Center

1500 Lomas Blvd NW, Suite B

Albuquerque, NM 87104

(505) 503-6490

info@OriginalMedicineABQ.com

AcupunctureMaintain health and balance in your bodys systems, restore function and promote healing with acupuncture. Learn more.

Chinese HerbsChinese herbal medicine is part of our integrated system of health care that has been around for thousands of years.

Lifestyle & Wellness Programs

Wellness is more than being free from illness it is a dynamic process of change and growth. We customize programs for your individual needs.

Our purpose is to provide the highest level of care so that people may lead happy, productive, pain-free and healthy lives naturally.

At Original Medicine, our licensed professionals have been helping people in and around Albuquerque stay healthy and feel better naturally since 2004. Our Functional Medicine approach combines Chinese medicine with modern testing to get a full picture of the body's health.

Through compassionate healthcare and wellness education, we inspire our patients to better understand their health and wellbeing while effectively treating their mind, body and spirit.

Some of the many services we offer include:

The rest is here:
Original Medicine Wellness Center - Functional Medicine ...

→←